

AD \_\_\_\_\_

GRANT NUMBER: DAMD17-94-J-4128

TITLE: The Role of the MAP Kinase Pathway in Breast Cancer

PRINCIPAL INVESTIGATOR: Melanie H. Cobb, Ph.D.

CONTRACTING ORGANIZATION: University of Texas Southwestern  
Medical Center at Dallas  
Dallas, Texas 75235-9016

REPORT DATE: October 1996

TYPE OF REPORT: Final

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970618 150

DTIC QUALITY INSPECTION

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> October 1996	<b>3. REPORT TYPE AND DATES COVERED</b> Final (12 Sep 94 - 11 Sep 96)	
<b>4. TITLE AND SUBTITLE</b> The Role of the MAP Kinase Pathway in Breast Cancer			<b>5. FUNDING NUMBERS</b> DAMD17-94-J-4128	
<b>6. AUTHOR(S)</b> Melanie H. Cobb, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Texas Southwestern Medical Center at Dallas Dallas, Texas 75235-9016			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			<b>10. SPONSORING/MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200)</b>  Growth factors may play an important role in the pathogenesis of breast cancer. The MAP kinase pathway may be essential for transformation caused growth factors. Thus, the purpose of this study is to determine if MAP kinases may be overexpressed or activated in breast cancer. About one-third of the breast cancer cell lines tested contained changes in the amounts of MAP kinases, although there was not one consistent pattern of alteration from the normal expression. An alteration in amount of any of the enzymes may be an indication of altered regulation of the pathway in the affected cells. Future experiments to further address this issue will focus on analyzing activation state and correlating changes in amounts of MAP kinases with stage of tumor. Newly available antibodies allow measurement of activated MAP kinases directly in cell lysates. These antibodies are being evaluated for use in immunocytochemistry of normal mammary epithelial cells and breast cancer cell lines. If these antibodies prove useful for immunocytochemistry, in the future tumors will be obtained from Dr. Gazdar of this institution so that activation state of MAP kinases can be measured in situ.				
<b>14. SUBJECT TERMS</b> Breast Cancer			<b>15. NUMBER OF PAGES</b> 20	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

✓ Where copyrighted material is quoted, permission has been obtained to use such material.

✓ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

✓ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Melanie H. Cobb 10-10-96  
PI - Signature Date  
Melanie H. Cobb, Ph.D.

## TABLE OF CONTENTS

FRONT COVER	1
REPORT DOCUMENTATION PAGE	2
FOREWORD	3
TABLE OF CONTENTS	4
INTRODUCTION	5
BODY	
<b>Experimental Methods</b>	
Immunodetection of enzymes of the MAP kinase pathway	6
Assessment of MAP kinase activities in tumor cells.	
<b>Results and Future Directions</b>	
Task 1. Immunodetection of enzymes of the MAP kinase pathway	6
Task 2. Assessment of MAP kinase activities in tumor cells.	
Task 3. Analysis of MAP kinases and their activities in situ	7
in breast tumors and preneoplastic states	8
CONCLUSIONS	8
REFERENCES	10
BIBLIOGRAPHY	11
PERSONNEL RECEIVING PAY	18
Attachment	

## (5) INTRODUCTION

Breast cancer is the most common cancer of women (1). Although therapies have been developed that are effective in selected subgroups of patients, these therapies have not had a great impact on breast cancer mortality rates. To develop new and more effective therapies for breast cancer it will be important to understand the pathogenesis of breast cancer in more detail. Breast cancer cells express tyrosine kinase receptors and may be induced to proliferate by their cognate growth factors (1). The role of growth factors in human breast cancer is further supported by the finding that the *erbB2* gene is amplified in 10-30% of breast cancers (2-10). The presence of this amplified gene correlates with a poor prognosis (2-10). Overexpression of ErbB2 in NIH 3T3 cells induces transformation, and expression of a mutant ErbB2 in transgenic mice results in development of adenocarcinomas of the breast in 100% of females (11-13). These data strongly support the conclusion that breast carcinoma cells are responsive to growth factors and support the hypothesis that these factors may play an important role in the pathogenesis of breast cancer.

Ras is an important signal transducer in the actions of tyrosine kinase receptors like those for ErbB2 and insulin. Activation of Ras leads to the activation of several downstream signaling pathways. Among these the best understood is the MAP kinase pathway (14). The GTP-bound form of Ras interacts with the protein kinase Raf, which, like Ras, is a proto-oncogene. The binding of Raf to Ras is thought to target Raf to the membrane where its protein kinase activity is increased. The enzymes activated by Raf, MAP kinase kinases or MEKs 1 and 2 (15), phosphorylate and activate the MAP kinases, ERK1 and ERK2. The MAP kinases ERK1 and ERK2 are pleiotropic regulatory enzymes activated in most if not all cell types by several of numerous hormones and growth factors. They phosphorylate many substrates, including certain other protein kinases and transcription factors, and have important growth regulatory functions. This pathway has also been implicated in the transforming activity of small t antigen (16).

Interfering with the functions of ERK1 and ERK2, using catalytically defective mutants of them, blocks 1) the actions of the oncogenic forms of Ras (17) and Raf in fibroblasts, 2) the transforming potency of small t antigen in CV-1 cells (16), and 3) cell proliferation induced by EGF (16). Constitutively active forms of the MAP kinases have not been identified either by genetic selection or by mutagenesis strategies (14). However, since this proposal was submitted, it has been shown that activated mutants of MEK1 transform fibroblasts in culture, cause their growth in soft agar, and result in the formation of tumors in nude mice (18). MEK1 is one of the major targets of Raf, but it is probably not the only Raf target; thus, transformation induced by activated MEK1 is likely due to a subset of the potential actions of Raf. As the MAP kinases are the only known substrates of MEK1, it is believed that activated MEK1 transforms by activating MAP kinases. These findings support the concept that activation of MAP kinase leads to cellular transformation. Therefore, we propose that this pathway may be altered in breast cancer, perhaps increasing sensitivity to growth factors and that the activity of this pathway may be critical for the proliferation of the cells.

Given these critical role of tyrosine kinase receptors in breast cancer and the recent results with activated MEK1, the original purpose of this research was to: 1) measure the amounts of MAP kinases and MEKs in normal breast tissue and a series of cells from malignant breast; 2) measure the sensitivity of MAP kinases in these cells to insulin, serum, and EGF; 3) determine if activated MEK1 will transform cells from normal breast tissue; and 4) determine if catalytically defective mutants of MAP kinases block proliferation of breast cancer cells. The methods, described in more detail below, are primarily immunoblotting and activity assays developed in our laboratories, and morphological transformation assays. Newly available antibodies, described below, have caused us to amend our original goals to include immunocytochemistry of freshly isolated tumors.

## **(6) BODY**

### **Experimental Methods**

**Immunodetection of enzymes of the MAP kinase pathway.** The amounts of the MAP kinases present in the normal and malignant cells have been identified by immunoblotting with antibodies to ERK1 and ERK2 (19). We have generated antibodies to both isoforms that will detect both proteins cleanly in whole cell lysates by immunoblotting. ERK1 and ERK2 each undergo a shift in electrophoretic mobility when they are in the active forms. Thus, a lysate containing only inactive ERK1 and ERK2 will display two immunoreactive species, ERK2 at ~41 kDa and ERK1 at ~43 kDa. If the proteins are both fully active, two bands at ~42 kDa and ~44 kDa will be present. In a lysate containing a mixture of active and inactive ERKs, all four bands will be present and resolved. The differences in mobility are easily detected by comparison to a standard.

**Measurement of MAP kinase activity.** Antibodies that selectively recognize the active forms of ERK1 and ERK2 were used for immunoblotting to detect the possibility of constitutive activation of ERK1/ERK2 in cell lines derived from tumors. Because these antibodies do not recognize 100-fold excess of the inactive kinases, they can reliably detect even very small amounts of activated ERK1 and ERK2 in whole cell lysates and we tested them for immunofluorescence as described under results of task 2 and will now proceed to test them for immunocytochemistry. We believe the methodology can be developed. Immunocytochemistry will be performed on freshly isolated tumors to determine the activation state of the MAP kinases in situ. This will allow us to determine if there is a relationship between tumor grade and MAP kinase pathway activity.

### **Results and future directions**

Due to considerations described in last year's progress report, the tasks redefined as our statement of work are as follows:

- Task 1. Immunodetection of enzymes of the MAP kinase pathway**
- Task 2. Assessment of MAP kinase activities in tumor cells.**
- Task 3. Analysis of MAP kinases and their activities in situ  
in breast tumors and preneoplastic states**

Progress will be described as it relates to these three tasks.

- Task 1. Immunodetection of enzymes of the MAP kinase pathway**
- Task 2. Assessment of MAP kinase activities in tumor cells.**

In the second year of this grant, immunoblotting methods were used to assess both amounts of (task1) and activities of (task 2) ERK1 and ERK2.

**Examination of the MAP kinase pathway in cells from nonsmall cell lung carcinomas (nSCLC).** Ten nSCLC cell lines have been studied to probe the possible role of the MAP kinase pathway in this type of cancer. Some of the cell lines expressed mutated forms of Ras. There was a consistent trend indicating a large increase in expression of ERK1 and a marked activation in a large proportion of the cells.

**Examination of the MAP kinase pathway in cells from human breast tumors and normal mammary epithelium.** We have examined MAP kinase amounts in a number of nonimmortalized lines from normal breast and breast carcinoma and lines from normal and malignant tissue that have been immortalized in the laboratory. Unlike normal bronchial epithelium, normal breast tissue has nearly equal amounts of ERK1 and ERK2. About one-third of the breast cancer cells contained changes in



the amounts of these MAP kinases. Again, unlike in nSCLC, there was not one consistent pattern of alteration from the normal expression of ERK1 and ERK2. In some lines there was relatively more ERK1 and in some there was relatively more ERK2. An alteration in amount of any of the enzymes may be an indication of altered regulation of the pathway in the affected cells. However, the marked variation makes it difficult to form an initial hypothesis about the role of the cascade in breast cancer. One question that we will address by looking at fresh samples rather than cell lines is are their consistent changes in amounts of MAP kinases in tumors or are the changes we see in cultured lines a consequence of their growth in culture. To focus on the activation state of the MAP kinases, we used the active ERK1/ERK2 antibody. Immunoblots showed that ~ half of the lines displayed activated ERK2.

Our current interpretation is that the kinases in the pathway are more highly activated by growth factors in the malignant cells, suggesting that the kinases are involved in enhanced growth factor sensitivity. Again, we plan to verify this hypothesis by examining tumors with antibodies that selectively detect active enzymes. Whether activation of this cascade is required for progression to the malignant phenotype will be examined by future experiments using dominant negative ERK mutants or activated MEK1 mutants.

**Task 3. Analysis of MAP kinases and their activities in situ  
in breast tumors and preneoplastic states**

To evaluate the possibility of using antibodies to detect activation states of ERKs in tissue, we have used the antibodies for immunofluorescence on fibroblasts. First we wished to determine if we could see differences in immunofluorescent signal in serum-deprived compared to serum- or growth factor-treated cells and to assess the sensitivity of the antiactive ERK antibodies. These antibodies were provided prior to their widespread commercial availability, so that we could evaluate their usefulness. We have used several batches of antibodies and have identified affinity purified antibodies from one rabbit that readily detect differences in activation state of ERKs in fixed cells. We are in the process of adapting them for tissue immunocytochemistry.

**Concerning the original tasks 2-4.** Of the originally proposed tasks # 2-4, to examine effects of activating or inhibiting MAP kinases on tumor proliferation, etc., based on results of task 1, there is no logical basis for performing the future experiments on the cell lines presently on hand. The marked variation makes it difficult to form an hypothesis about the role of the cascade in breast cancer. Because of that variation in behavior of the cell lines, it seemed apparent that only actual tumor samples would suggest if there was any significant component of breast cancers that might relate in a meaningful way to the MAP kinase pathway. Nevertheless, we did analyze a large series of breast cancer and other tumor-derived cell lines for the presence of a regulatory subunit of phosphatase 2a, which has been implicated in inactivation of MAP kinases in transformed cells, and for the activation state of the MAP kinases, using antibodies that selectively immunoblot the activated forms. Our original analysis of MAP kinase activities in these lines, based on in vitro kinase assays which are more subject to misinterpretation, was inconclusive. A table of these studies and a summary of the results are included. In anticipation of performing the originally proposed tasks we have prepared and obtained the complete group of recombinant adenoviruses that would have been required, including ones that express wt and catalytically defective ERK2. These have been tested in three cell lines to confirm that they have the expected properties.

Our comparison of activities in small cell and nonsmall cell lung cancer cell lines was valuable for this study, because it shows that consistent changes in amounts and behavior of MAP kinases can be expected in certain tumor-derived cell types and that such changes depend on cell type. For example, in cell lines from nonsmall cell lung cancers, there is a consistent increase in the amount of

ERK2. This type of consistent change allows experiments to be performed in a meaningful context. In the breast cancer cells, all possible combinations of behavior were detected. The amounts of either the MAP kinases ERK1 or ERK2 went up or went down and in some, but not all, cases activities were elevated in a manner apparently not related to enzyme amounts. The results from the breast cancer cells indicate that important variables are not controlled that relate to the cell lines themselves.

## (7) CONCLUSIONS

About one-third of the breast cancer cells contained changes in the amounts of MAP kinases, although there was not one consistent pattern of alteration from the normal expression. An alteration in amount of any of the enzymes is consistent with altered regulation of the pathway in the affected cells. Approximately half showed an increase in ERK2 activity, which suggests that the enhanced proliferation of the cells may relate to increased MAP kinase activity. Future experiments will focus on correlating MAP kinase activities with stage of tumor by immunocytochemistry in tumors obtained from Dr. Gazdar of this institution for this analysis. A publication concerning the work on MAP kinase amounts and activities is in preparation.

### Western Result Summary

Cell Type	Activated ERK 1/2 (Ab)	ERK 1/2 (Y691)	PP2A (Ba)
NSCLC	8/8; 5/8 ERK2>ERK1, 1/8 only ERK2	8/8; 1/8 ONLY ERK2	8/8.
SCLC	1/14 (ERK2>ERK1)	14/14	14/14
Breast	10/17 (ERK2>ERK1)	17/17	17/17
V trans. B cells	0/2		



**Western Blot**

Lysate Number	Cell Lysate	Activated ERK 1/2 (Ab)	ERK 1/2 (Y691)	PP2A (Ba)
YE001	H358	yes (faint)	yes	yes
YE017a	H157	yes (ERK 2 > ERK 1)		
YE020b	BL-5	no		
YE023a	BL1770	no		
bbp3	H524	no	yes	yes
bbp14	SCC1187	no		
bbp15	HTB131	no		
bbp16	HTB22	no		
bbp17	HTB129	yes (ERK 2, faint)		
bbp18	HTB26	yes (ERK 2 > ERK 1)		
bbp19	HTB121	no	yes	yes
bbp20a	SCC38	yes (ERK 2 > ERK 1)		
bbp20b	SCC38	yes (ERK 2 > ERK 1)		
bbp21a	HTB24	yes (ERK 2 > ERK 1)		
bbp21b	HTB24	yes (ERK 2 > ERK 1)		
bbp22a	HTB130	yes (ERK 2, very faint)		
bbp22b	HTB130	yes (ERK 2, very faint)		
bbp23b	HTB132	yes (ERK 2 > ERK 1)	yes	yes (faint)
bbp24a	HTB133			
bbp24b	HTB133	yes (faint)		
bbp25b	HTB19	no	yes	no
bbp26b	HTB23			
bbp27a	HTB27			
bbp27b	HTB27			
bbp28b	HTB20			
bbp29a	HTB25			
bbp29b	HTB25	yes (ERK 2 > ERK 1)		
bbp30b	H345	no	yes	yes
bbp31b	H220	no	yes	yes
bbp32b	H592	no	yes	yes
bbp33b	H748	no	yes	yes
bbp34b	H2198	yes (ERK 2, faint)	yes	yes
bbp35b	H738	no	yes	yes
bbp36b	H1688	no	yes	yes
bbp37b	H889	no	yes	yes
bbp38b	H1607	no	yes	yes
bbp39b	H1994	no	yes	yes
bbp40b	H2028	no	yes	yes
bbp41b	H740	no	yes	yes
bbp42b	H1450	no	yes	yes
	H1334 no stim	yes (faint)	yes	yes (faint)
	H1334 30' stim	yes	yes	yes
11/15/95	NHBE no stim	ERK 2 (faint)	yes	yes
11/15/95	NHBE 24 hr stim	ERK 2 (+faint ERK 1)	yes	yes (faint)

**Western Blot**

	H1792 0'stim	yes (ERK 2 only)	yes	yes
	H1792 30' stim	yes (ERK 2 > ERK 1)	yes	yes
	H1466 0' stim	yes (ERK 2 > ERK 1)	yes	yes
	H1466 30' stim	yes (ERK 2 > ERK 1)	yes	yes
11/17/95	NHBE no stim	no	no	yes
11/17/95	NHBE 24 hr stim	yes (ERK 2 > ERK 1)	yes	no
	PC12 NGF stim	yes	yes	yes
	PC12 no stim	yes (very faint)	yes	yes

**HTBs and SPCs are breast cancer cells. NHs are normal epithelium.**

**(8) REFERENCES**

1. M. E. Lippman, *Science* **259**, 631 (1993).
2. S. Kobayashi, *et al*, *Japanese Journal of Cancer Research* **83**, 859 (1992).
3. H. C. Maguire, Jr., M. I. Greene, *Pathobiology* **58**, 297 (1990).
4. R. M. Hudziak, *et al*, *Proceedings of the National Academy of Sciences of the United States of America* **85**, 5102 (1988).
5. D. J. Slamon, G. M. Clark, *Science* **240**, 1795 (1988).
6. C. R. King, M. H. Kraus, S. A. Aaronson, *Science* **229**, 974 (1985).
7. D. C. Allred, *et al*, *Journal of Clinical Oncology* **10**, 599 (1992).
8. D. C. Allred, *et al*, *Human Pathology* **23**, 974 (1992).
9. D. J. Slamon, *et al*, *Science* **244**, 707 (1989).
10. D. J. Slamon, *et al*, *Science* **235**, 177 (1987).
11. R. M. Hudziak, J. Schlessinger, A. Ullrich, *Proceedings of the National Academy of Sciences of the United States of America* **84**, 7159 (1987).
12. P. P. Di Fiore, *et al*, *Science* **237**, 178 (1987).
13. W. J. Muller, E. Sinn, P. K. Pattengale, R. Wallace, P. Leder, *Cell* **54**, 105 (1988).
14. M. H. Cobb, E. Goldsmith, *J. Biol. Chem.* **270**, 14843 (1995).

15. R. Seger, *et al*, *J. Biol. Chem.* **267**, 14373 (1992).
16. E. Sontag, S. Federov, D. Robbins, M. Cobb, M. Mumby, *Cell* **75**, 887 (1993).
17. J. A. Frost, T. D. Geppert, M. H. Cobb, J. R. Feramisco, *Proc. Natl. Acad. Sci. USA* **91**, 3844 (1994).
18. S. J. Mansour, *et al*, *Science* **265**, 966 (1994).
19. T. G. Boulton, M. H. Cobb, *Cell Regulation* **2**, 357 (1991).

**(11) BIBLIOGRAPHY & PERSONNEL RECEIVING PAY:**

**PUBLICATIONS:**

1. Garland R. Marshall, H. E. Bosshard, N. C. Kendrick, J. Turk, T. M. Balasubramanian, Melanie H. Cobb, M. Moore, L. LeDuc and P. Needleman.  $\alpha$ -Methyl Amino Acids in Peptide Chemistry. In: *Peptides 1976* (Loffet, A., ed., Editions de l'Université de Bruxelles, Bruxelles, Belgium, 1976) pp. 361-369.
2. Jean Danner, Howard M. Lenhoff, Melanie H. Cobb, Wyrta Heagy and Garland R. Marshall. Interaction of Hydra  $\gamma$ -Glutamyl Transpeptidase with GSH Analogs. *Biochem. Biophys. Res. Comm.*, **73**:180-186, 1976.
3. Jean Danner, Melanie H. Cobb, Wyrta Heagy, Howard M. Lenhoff and Garland R. Marshall. Glutathione Analogues: Interaction with Hydra attenuata  $\gamma$ -Glutamyltransferase. *Biochem. J.*, **175**:547-553, 1978.
4. Walter N. Scott, Melanie H. Cobb, Stephen L. Slatin, Irwin M. Reich, Chia-Ping H. Yang. Membrane Events Related to Hormone Stimulation of Sodium Transport in Toad Urinary Bladder. In: *Epithelial Transport* (INSERM Symposium Series, Paris), Vol. 85:63-70, 1979.
5. Melanie H. Cobb and Walter N. Scott. Insulin-Stimulated Sodium Transport in Toad Urinary Bladder. In: *Peptides: Structure and Biological Function* (E. Gross, J. Meienhofer, eds, Pierce Chem. Co., Rockville, IL, 1979), pp. 881-884.
6. Melanie H. Cobb and Walter N. Scott. Mechanisms of Insulin-Stimulated Sodium Transport. *Ann. N.Y. Acad. Sci.*, **358**:334-336, 1980.
7. Melanie H. Cobb, Wyrta Heagy, Jean Danner, Howard M. Lenhoff and Garland R. Marshall. Effect of Glutathione on Cyclic Nucleotide Levels in Hydra attenuata. *Comp. Biochem. Physiol.*, **65C**:111-115, 1980.
8. Douglas M. Jefferson, Melanie H. Cobb, Joseph F. Gennaro and Walter N. Scott. Transporting Renal Epithelium: Culture in Hormonally Defined, Serum-Free Medium. *Science*, **210**:912-914, 1980.
9. Walter N. Scott, Stephen L. Slatin, Melanie H. Cobb and Irwin M. Reich. Insulin-Induced Alterations in the Lactoperoxidase-Catalyzed Radioiodination of Membrane Proteins of the Toad Urinary Bladder Epithelium. *Endocrinol.*, **109**:1775-1777, 1981.

10. Melanie H. Cobb, Irene A. Skipski and Walter N. Scott. Role of Insulin-Induced Proteins in Transepithelial Na Transport. *Ann. N.Y. Acad. Sci.*, 372:247-271, 1981.
11. Melanie H. Cobb and Walter N. Scott. Irreversible Inhibition of Sodium Transport in Toad Bladder by Photolysis of Amiloride Analogs. *Experientia*, 37:68-69, 1981.
12. Walter N. Scott, Chia-Ping H. Yang, Irene A. Skipski, Melanie H. Cobb, Irwin M. Reich and Phillip M. Terry. Biosynthetic Processes Related to Aldosterone's Stimulation of Na Transport in the Toad Urinary Bladder. *Ann. N.Y. Acad. Sci.*, 372:15-29, 1981.
13. Douglas M. Jefferson, Melanie H. Cobb, Joseph F. Gennaro and Walter N. Scott. Properties of a Transporting Primary Kidney Epithelial Cell Line. *Ann. N.Y. Acad. Sci.*, 372:473-479, 1981.
14. Chia-Ping H. Yang, Melanie H. Cobb, Douglas M. Jefferson and Walter N. Scott. Effects of Mineralocorticoids on RNA and Protein Synthesis in MDCK cells. *Ann. N.Y. Acad. Sci.*, 372:470-472, 1981.
15. Melanie H. Cobb, Chia-Ping H. Yang and Walter N. Scott. Effects of Insulin on RNA Synthesis in Toad Urinary Bladder. *Endocrinology*, 109:2167-2174, 1981.
16. Ora M. Rosen, Charles S. Rubin, Melanie H. Cobb and Charles J. Smith. Insulin Promotes the Phosphorylation of Ribosomal Protein S6 in 3T3-L1 Preadipocytes. *Cold Spring Harbor Conferences on Cell Proliferation*, Vol. 8, 771-781, 1981.
17. Melanie H. Cobb, Irene A. Skipski, Irwin M. Reich, Stephen L. Slatin and Walter N. Scott. Induction of Proteins in the Toad Urinary Bladder by Insulin. *Biochem. J.*, 200:17-25, 1981.
18. Ora M. Rosen, Charles S. Rubin, Melanie H. Cobb and Charles J. Smith. Insulin Stimulates the Phosphorylation of Ribosomal Protein S6 in a Cell-Free System Derived from 3T3-L1 Preadipocytes. *J. Biol. Chem.*, 256:3630-3633, 1981.
19. Wyrta Heagy, Jean Danner, Melanie H. Cobb, Howard M. Lenhoff and Garland R. Marshall. Azaserine Affinity Labeling of  $\gamma$ -Glutamyl transferase of Hydra attenuata Without Inactivation of the Glutathione Feeding Receptor. *J. Exp. Biol.*, 101:287-293, 1982.
20. Melanie H. Cobb, Wyrta Heagy, Jean Danner, Howard M. Lenhoff and Garland R. Marshall. Structural and Conformational Properties of Peptides Interacting with the Glutathione Receptor of Hydra. *Molec. Pharmacol.*, 21:629-636, 1982.
21. Lilli M. Petruzzelli, Sabyasachi Ganguly, Charles J. Smith, Melanie H. Cobb, Charles S. Rubin and Ora M. Rosen. Insulin Activates a Tyrosine-Specific Protein Kinase in Extracts of 3T3-L1 Adipocytes and Human Placenta. *Proc. Natl. Acad. Sci. USA*, 79:6792-6796, 1982.
22. Melanie H. Cobb, Chia-Ping. H. Yang, Douglas M. Jefferson, Elizabeth M. Pasnikowski and Walter N. Scott. Aldosterone-Induced Proteins in Canine Kidney Cells. *Mol. Cell Endocrinol.*, 27:129-137, 1982.
23. Ora M. Rosen, Roman Herrera, Yetunde Olowe, Lilli M. Petruzzelli and Melanie H. Cobb. Phosphorylation Activates the Insulin Receptor Tyrosine Protein Kinase. *Proc. Natl. Acad. Sci. USA*, 80:3237-3240, 1983.

24. Melanie H. Cobb and Ora M. Rosen. Description of a Protein Kinase Derived from Insulin-Treated 3T3-L1 Cells that Catalyzes the Phosphorylation of Ribosomal Protein S6 and Casein. *J. Biol. Chem.*, 258:12472-12481, 1983.
25. Melanie H. Cobb and Ora M. Rosen. The Insulin Receptor and Tyrosine Protein Kinase Activity. *Biochim. Biophys. Acta (Cancer)*, 738:1-8, 1984.
26. Douglas M. Jefferson, Chia-Ping H. Yang, Melanie H. Cobb and Walter N. Scott. A Comparison of Protein Synthetic Patterns of MDCK Cells Grown in Serum and Hormonally Defined Serum-Free Medium. *J. Cell. Physiol.*, 123:126-131, 1985.
27. Robert Smith, Melanie H. Cobb, Ora M. Rosen and Leonard Jarrett. Ultrastructural Analysis of the Organization and Distribution of Insulin Receptors on the Surface of 3T3-L1 Adipocytes: Rapid Microaggregation and Migration of Occupied Receptors. *J. Cell. Physiol.*, 123:167-179, 1985.
28. Melanie H. Cobb, Chia-Ping H. Yang, James Brown and Walter N. Scott. Insulin-Stimulated Sodium Transport in Toad Urinary Bladder. *Biochim. Biophys. Acta*, 856:123-129, 1986.
29. Melanie H. Cobb, John G. Burr, Maurine E. Linder, Teri B. Gray and Jill S. Gregory. A Similar Ribosomal Protein S6 Kinase Activity Is Found in Insulin-Treated 3T3-L1 Cells and Chick Embryo Fibroblasts Transformed by Rous Sarcoma Virus. *Biochem. Biophys. Res. Comm.*, 137:702-708, 1986.
30. Melanie H. Cobb. An Insulin-Stimulated Ribosomal Protein S6 Kinase. *J. Biol. Chem.*, 261:12994-12999, 1986.
31. Leland Ellis, Alla Levitan, Melanie H. Cobb and Purita Ramos. Efficient Expression in Insect Cells of a Soluble, Active Human Insulin Receptor Protein-Tyrosine Kinase Domain by Use of a Baculovirus Vector. *J. Virol.*, 62:1634-1639, 1988.
32. Jill S. Gregory, Teri G. Boulton, Bi-Ching Sang and Melanie H. Cobb. An Insulin-stimulated Ribosomal Protein S6 Kinase from Rabbit Liver. *J. Biol. Chem.*, 264:18397-18401, 1989.
33. Melanie H. Cobb, Bi-Ching Sang, Roberto Gonzalez, Elizabeth Goldsmith, and Leland Ellis. Autophosphorylation Activates the Soluble Cytoplasmic Domain of the Insulin Receptor in an Intermolecular Reaction. *J. Biol. Chem.* 264:18701-18706, 1989.
34. Teri G. Boulton, Jill S. Gregory, Song-Muh Jong, Lu-Hai Wang, Leland Ellis and Melanie H. Cobb. Evidence for Insulin-dependent Activation of S6 and Microtubule-associated Protein-2 Protein Kinases via a Human Insulin Receptor/v-Ros Hybrid. *J. Biol. Chem.* 265:2713-2719, 1990.
35. Teri G. Boulton, George D. Yancopoulos, Jill S. Gregory, C. Slaughter, C. Moomaw, J. Hsu, and Melanie H. Cobb. An Insulin-Stimulated Protein Kinase Homologous to Yeast Kinases Involved in Cell Cycle Control. *Science* 249:64-67, 1990.
36. Teri G. Boulton, Jill S. Gregory and Melanie H. Cobb. Purification and Properties of Extracellular Signal-regulated Kinase 1, an Insulin-Stimulated Microtubule-associated Protein 2 Kinase. *Biochemistry* 30:278-286, 1991.

37. George D. Yancopoulos, Peter C. Maisonpierre, Nancy Y. Ip, Thomas H. Aldrich, Leonardo Belluscio, Teri G. Boulton, Melanie H. Cobb, Stephen P. Squinto and Mark E. Furth. Neurotrophic Factors, Their Receptors, and the Signal Transduction Pathways They Activate. Cold Spring Harbor Symp. Quant. Biol. Vol. 55, 371-379, 1990.
38. Teri G. Boulton and Melanie H. Cobb. Identification of Multiple Extracellular Signal-Regulated Kinases (ERKs) with Antipeptide Antibodies. Cell Regulation 2:357-371, 1991.
39. Teri G. Boulton, Steven H. Nye, David J. Robbins, Nancy Y. Ip, Elizabeth Radziejewska, Sharon D. Morgenbesser, Ronald A. DePinho, Nikos Panayotatos, Melanie H. Cobb and George D. Yancopoulos. ERKs: A Family of Protein-Serine/Threonine Kinases that Are Activated and Tyrosine Phosphorylated in Response to Insulin and NGF. Cell 65:663-675, 1991.
40. Rony Seger, Natalie G. Ahn, Teri G. Boulton, George D. Yancopoulos, Nikos Panayotatos, Elizabeth Radziejewska, Lowell Ericsson, Rebecca L. Bratlien, Melanie H. Cobb, and Edwin G. Krebs. Microtubule-associated Protein 2 Kinases, ERK1 and ERK2, Undergo Autophosphorylation on Both Tyrosine and Threonine Residues: Implications for Their Mechanism of Activation. Proc. Natl. Acad. Sci. USA, 88:6142-6146, 1991.
41. Joie Rowles, Clive Slaughter, Carolyn Moomaw, Joan Hsu, and Melanie H. Cobb. Purification of Casein Kinase I and Isolation of cDNAs Encoding Multiple Casein Kinase I-like Enzymes. Proc. Natl. Acad. Sci. USA, 88:9548-9552, 1991.
42. Joan Ruderman, Frank Luca, Ellen Shibuya, Kim Gavin, Teri Boulton, and Melanie Cobb. Control of the Cell Cycle in Early Embryos. Cold Spring Harbor Symp. Quant. Biology, 56:495-502, 1991.
43. Melanie H. Cobb, Teri G. Boulton, and David J. Robbins. Extracellular Signal-Regulated Kinases: ERKs in Progress. Cell Regulation 2:965-978, 1991.
44. Melanie H. Cobb, David J. Robbins, and Teri G. Boulton. ERKs, Extracellular Signal-Regulated MAP2 Kinases. Curr. Opin. Cell Biol. 3:1025-1032, 1991.
45. Yoko Funasaka, Teri Boulton, Melanie Cobb, Yosef Yarden, B. Fan, Stewart D. Lyman, Douglas E. Williams, Dirk M. Anderson, Rena Zakut, Yutaka Mishima and Ruth Halaban. c-Kit Kinase Induces a Cascade of Protein Tyrosine Phosphorylation in Normal Human Melanocytes in Response to Mast Cell Growth Factor and Stimulates Mitogen-Activated Protein Kinase But is Down-regulated in Melanomas. Molec. Biol. of the Cell 3:197-209, 1992.
46. Ruey-min Lee, Melanie H. Cobb, and Perry J. Blackshear. Evidence that Extracellular Signal-regulated Kinases are the Insulin-activated Raf-1 Kinase Kinases. J. Biol. Chem. 267:1088-1092, 1992.
47. Hajime Owaki, Robert Makar, Teri G. Boulton, Melanie H. Cobb, and Tom D. Geppert. Extracellular Signal-Regulated Kinases in T Cells: Characterization of Human ERK1 and ERK2 cDNAs. Biochem. Biophys. Res. Comm. 182:1416-1422, 1992.
48. Natalie G. Ahn, David J. Robbins, John W. Haycock, Rony Seger, Melanie H. Cobb, and Edwin G. Krebs. Identification of an Activator of the Microtubule-associated Protein 2 Kinases ERK1 and ERK2 in PC12 Cells Stimulated with Nerve Growth Factor or Bradykinin. J. Neurochem.,



59:147-156, 1992.

49. David J. Robbins and Melanie H. Cobb. Extracellular Signal-Regulated Kinase 2 Autophosphorylates on a Subset of Peptides Phosphorylated in Intact Cells in Response to Insulin and Nerve Growth Factor: Analysis by Peptide Mapping. *Mol. Biol. Cell* 3:299-308, 1992.
50. John W. Haycock, Natalie G. Ahn, Melanie H. Cobb and Edwin G. Krebs. ERK1 and ERK2, Two Microtubule-Associated Protein 2 Kinases, Mediate the Phosphorylation of Tyrosine Hydroxylase at Serine-31 *in situ*. *Proc. Natl. Acad. Sci. USA*, 89:2365-2369, 1992.
51. Charles Whitehurst, Teri G. Boulton, Melanie H. Cobb, and Thomas D. Geppert. Extracellular Signal-regulated Kinases in T Cells. Anti-CD3 and 4 $\beta$ -Phorbol 12-Myristate 13-Acetate-Induced Phosphorylation and Activation. *J. Immunol.* 148:3230-3237, 1992.
52. Rony Seger, Natalie G. Ahn, James Posada, Erlynda S. Munar, Amy M. Jensen, Jonathan A. Cooper, Melanie H. Cobb, and Edwin G. Krebs. Purification and Characterization of Mitogen-activated Protein Kinase Activator(s) from Epidermal Growth Factor-Stimulated A431 Cells. *J. Biol. Chem.*, 267:14373-14381, 1992.
53. David J. Robbins., Mangeng Cheng, Erzhen Zhen, Colleen A. Vanderbilt, Larry A. Feig, and Melanie H. Cobb. Evidence for a Ras-dependent Extracellular Signal-regulated Protein Kinase (ERK) Cascade. *Proc. Natl. Acad. Sci. USA*, 89:6924-6928, 1992.
54. Ellen K. Shibuya, Teri G. Boulton, Melanie H. Cobb, and Joan V. Ruderman. Activation of p42 MAP Kinase and the Release of Oocytes from Cell Cycle Arrest. *EMBO J.*, 11:3963-3975, 1992.
55. D.N. Drechsel, A.A. Hyman, Melanie H. Cobb, and M.W. Kirschner. Modulation of the Dynamic Instability of Tubulin Assembly by the Microtubule-associated Protein Tau. *Mol. Biol. Cell.* 3:1141-1154, 1992.
56. Ruth Halaban, Jeffrey S. Rubin, Yoko Funasaka, Melanie Cobb, Teri Boulton, Donna Faletto, Eliot Rosen, Andrew Chan, Karen Yoko, Wain White, Christopher Cook, and Gisela Moellman. Met and Hepatocyte Growth Factor/Scatter Factor Signal Transduction in Normal Melanocytes and Melanoma Cells. *Oncogene* 7:2195-2206, 1992.
57. David M. Loeb, Hensin Tsao, Melanie H. Cobb, and Lloyd A. Greene. NGF and Other Growth Factors Induce an Association Between ERK 1 and the NGF Receptor, gp140<sup>prototr</sup>. *Neuron* 9:1053-1065, 1992.
58. David J. Robbins, Erzhen Zhen, Hajime Owaki, Colleen A. Vanderbilt, Douglas Ebert, Thomas D. Geppert, and Melanie H. Cobb. Regulation and Properties of Extracellular Signal-regulated Protein Kinases 1 and 2 *in vitro*. *J. Biol. Chem.* 268:5097-5106, 1993.
59. Jiin-Tsuey Cheng, Melanie H. Cobb, and Richard Baer. Phosphorylation of the TAL1 Oncoprotein by the Extracellular Signal-Regulated Protein Kinase ERK1. *Mol. Cell. Biol.* 13:801-808, 1993.
60. Faming Zhang, David J. Robbins, Melanie H. Cobb, and Elizabeth J. Goldsmith. Crystallization and Preliminary X-ray Studies of Extracellular Signal-regulated Kinase-2/MAP Kinase with an

Incorporated His-tag. *J. Mol. Biol.* 233:550-552, 1993.

61. David J. Robbins, Erzhen Zhen, Mangeng Cheng, Shuichan Xu, Colleen A. Vanderbilt, Douglas Ebert, Clark Garcia, Alphonsus Dang, and Melanie H. Cobb. Regulation and Properties of Extracellular Signal-Regulated Protein Kinases 1, 2, and 3. *J. Am. Soc. Nephrol.*, 4:1104-1110, 1993.
62. Marie-Hélène Verlhac, Henri de Pennart, Bernard Maro, Melanie H. Cobb, and Hugh J. Clarke. MAP Kinase Becomes Stably Activated at Metaphase and Is Associated with Microtubule-Organizing Centers during Meiotic Maturation of Mouse Oocytes. *Dev. Biol.* 158:330-340, 1993.
63. Estelle Sontag, Sergei Federov, Craig Kamibayashi, David Robbins, Melanie Cobb, and Marc Mumby. The Interaction of SV40 Small Tumor Antigen With Protein Phosphatase 2A Stimulates the MAP Kinase Pathway and Induces Cell Proliferation. *Cell* 75:887-897, 1993.
64. Faming Zhang, Arne Strand, David Robbins, Melanie H. Cobb, and Elizabeth J. Goldsmith. Atomic Structure of the MAP Kinase ERK2 at 2.3Å Resolution. *Nature*, 367:704-711, 1994.
65. David J. Robbins, Erzhen Zhen, Mangeng Cheng, Shuichan Xu, Douglas Ebert, and Melanie H. Cobb. MAP Kinases ERK1 and ERK2: Pleiotropic Enzymes in a Ubiquitous Signaling Network. *Adv. Cancer Res.*, 63:93-116, 1994.
66. Jeff A. Frost, Tom D. Geppert, Melanie H. Cobb, and James R. Feramisco. A Requirement for Extracellular Signal-regulated Kinase (ERK) Function in the Activation of AP-1 by Ha-Ras, Phorbol 12-myristate 13-acetate, and Serum. *Proc. Natl. Acad. Sci. USA*, 91:3844-3848, 1994.
67. Ying Xia, Larn-Yuan Hwang, Melanie H. Cobb, and Richard Baer. Products of the TAL2 Oncogene in Leukemic T Cells: bHLH Phosphoproteins with DNA-binding Activity. *Oncogene*, 9:1437-1446, 1994.
68. David J. Robbins, Erzhen Zhen, Mangeng Cheng, Colleen A. Vanderbilt, Douglas Ebert, Clark Garcia, Alphonsus Dang, and Melanie H. Cobb. Extracellular Signal-regulated Protein Kinases (ERKs) 1, 2, and 3. In: "The Cell Cycle", V. W. Hu, ed., Plenum Press, New York, pp 61-67, 1994.
69. Melanie H. Cobb, Jessie E. Hepler, Mangeng Cheng, and David Robbins. The Mitogen-activated Protein Kinases, ERK1 and ERK2. *Seminars in Cancer Biology* 5:1-8, 1994.
70. John K. Westwick, Adrienne D. Cox, Channing J. Der, Melanie H. Cobb, Masahiko Hibi, Michael Karin, and David A. Brenner. Oncogenic Ras Activates c-Jun via a Separate Pathway from the Activation of Extracellular Signal-regulated Kinases. *Proc. Natl. Acad. Sci. USA*, 91:6030-6034, 1994.
71. Audrey Minden, Anning Lin, Tod Smeal, Benoit Dérjard, Melanie Cobb, Roger Davis and Michael Karin. c-Jun N-Terminal Phosphorylation Correlates with Activation of the JNK Subgroup but Not the ERK Subgroup of Mitogen-Activated Protein Kinases. *Mol. Cell. Biol.*, 14:6683-6688, 1994.
72. Guy L. James, Michael S. Brown, Melanie H. Cobb, and Joseph L. Goldstein. Benzodiazepine Peptidomimetic BZA-5B Interrupts the MAP Kinase Activation Pathway in H-Ras-Transformed

Rat-1 Cells, But Not in Untransformed Cells. *J. Biol. Chem.*, 269:27705-27714, 1994.

73. Isobel A. Wadman, Hai-Ling Hsu, Melanie H. Cobb and Richard Baer. The MAP Kinase Phosphorylation Site of TAL1 Occurs Within a Transcriptional Activation Domain. *Oncogene*, 9:3713-3716, 1994.
74. Elizabeth Goldsmith and Melanie Cobb. Protein Kinases. *Curr. Opin. Structural Biol.*, 4:833-840, 1994.
75. Melanie H. Cobb, Shuichan Xu, Jessie E. Hepler, Michele Hutchison, Jeff Frost and David Robbins. Regulation of the MAP Kinase Cascade. *Cell. Mol. Biol. Res.* 40:253-256, 1994.
76. Melanie H. Cobb, Jessie E. Hepler, Erzhen Zhen, Doug Ebert, Mangeng Cheng, Alphonsus Dang, and David Robbins. Regulation and Structure of the MAP Kinases ERK1 and ERK2. In: *Alzheimers Disease, Lessons from Cell Biology*, pp 78-87, 1995.
77. Hendrik Gille, Monika Kortenjann, Oliver Thoma, Carolyn Moomaw, Clive Slaughter, Melanie H. Cobb, and Peter E. Shaw. ERK Phosphorylation Potentiates Elk-1-mediated Ternary Complex Formation and Transactivation. *EMBO J.*, 14:951-962, 1995.
78. Melanie H. Cobb and Elizabeth Goldsmith. How MAP Kinases are Regulated. *J. Biol. Chem.*, 270:14843-14846, 1995.
79. Lanmin Zhai, Paul R. Graves, Lucy C. Robinson, Michelle Italiano, Michael R. Culbertson, Joie Rowles, Melanie H. Cobb, Anna A. DePaoli-Roach and Peter J. Roach. Casein Kinase I $\gamma$  Subfamily: Molecular Cloning, Expression and Characterization of Three Mammalian Isoforms, and Complementation of Defects in the *Saccharomyces cerevisiae* YCK Genes. *J. Biol. Chem.*, 270:12717-12724, 1995.
80. Jiandong Zhang, Faming Zhang, Douglas Ebert, Melanie H. Cobb, and Elizabeth J. Goldsmith. The Activity of the MAP Kinase ERK2 Is Controlled by a Flexible Surface Loop. *Structure* 3:299-307, 1995.
81. Stevan Marcus, Anthony Pulverino, Eric Chang, David Robbins, Melanie H. Cobb, and Michael H. Wigler. Shk1, a Homolog of the *Saccharomyces cerevisiae* Ste20 and Mammalian p65<sup>PAK</sup> Protein Kinases, is a Component of a Ras/Cdc42 Signaling Module in the Fission Yeast *Schizosaccharomyces pombe*. *Proc. Natl. Acad. Sci. USA*, 92:6180-6184, 1995.
82. Shuichan Xu, David Robbins, Jeff Frost, Alphonsus Dang, Carol Lange-Carter, and Melanie H. Cobb. MEKK1 Phosphorylates MEK1 and MEK2 but Does Not Cause Activation of Mitogen-activated Protein Kinase. *Proc. Natl. Acad. Sci. USA*, 92:6808-6812, 1995.
83. Melanie H. Cobb. MAP Kinases ERK1 and ERK2. In: *Protein Kinase Fact Book*, Academic Press, pp 214-216, 1995.
84. Melanie H. Cobb. ERK3. In: *Protein Kinase Fact Book*, Academic Press, pp 217-218, 1995.
85. Melanie H. Cobb. Casein Kinase I. In: *Protein Kinase Fact Book*, Academic Press, pp 347-349, 1995.

86. Anthony Polverino, Jeff Frost, Peirong Yang, Michele Hutchison, Aaron M. Neiman, Melanie H. Cobb, and Stevan Marcus. Activation of MAPK Cascades by p21-activated Protein Kinases in Cell-Free Extracts of *Xenopus* Oocytes. *J. Biol. Chem.* 270:26067-26070, 1995.
87. Jessie M. English, Colleen A. Vanderbilt, Shuichan Xu, Stevan Marcus, and Melanie H. Cobb. Isolation of MEK5 and Differential Expression of Alternatively Spliced Forms. *J. Biol. Chem.*, 270:28897-28902, 1995.
88. Mangeng Cheng, Teri G. Boulton, and Melanie H. Cobb. ERK3 is a Constitutively Nuclear Protein Kinase. *J. Biol. Chem.*, 271:8951-8958, 1996.
89. Mangeng Cheng, Erzhen Zhen, Megan J. Robinson, Doug Ebert, Elizabeth Goldsmith, and Melanie H. Cobb. Characterization of a Protein Kinase that Phosphorylates the MAP Kinase Homolog ERK3. *J. Biol. Chem.*, 271:12057-12062, 1996.
90. Megan J. Robinson, Paul C. Harkins, Jiandong Zhang, Richard Baer, John W. Haycock, Melanie H. Cobb, and Elizabeth J. Goldsmith. Mutation of Position 52 in ERK2 Creates a Nonproductive Binding Mode for ATP. *Biochemistry*, 35:5641-5646, 1996.
91. Shuichan Xu, David J. Robbins, Lori B. Christerson, Jessie M. English, Colleen A. Vanderbilt and Melanie H. Cobb. Cloning of Rat MEKK1 cDNA Reveals an Endogenous Membrane-Associated 195 kDa Protein with a Large Regulatory Domain. *Proc. Natl. Acad. Sci. USA*, 93:5291-5295, 1996.
92. Jeffrey A. Frost, Shuichan Xu, Michele R. Hutchison, Stevan Marcus, and Melanie H. Cobb. Actions of Rho Family Small G Proteins and p21-Activated Protein Kinases on Extracellular Signal-Regulated Protein Kinases, c-Jun N-Terminal Kinase/Stress-Activated Protein Kinase, and p38 Mitogen-Activated Protein Kinases. *Molec. Cell. Biol.*, 16:3703-3713, 1996.
93. Yi-Chi Su, Jiahuai Han, Shuichan Xu, Melanie Cobb, and Edward Y. Skolnik. Identification of a Novel Serine/Threonine Protein Kinase That Binds the SH3 Domains of Nck and Activates the MEKK1-MKK4-JNK/SAPK Signaling Pathway. *EMBO J.*, accepted pending revisions, 1996.
94. Megan J. Robinson, Mangeng Cheng, Andrei Khokhlatchev, Doug Ebert, Natalie Ahn, Kun-Liang Guan, Bernd Stein, Elizabeth Goldsmith, and Melanie H. Cobb. Contribution of the MAP Kinase Backbone and Phosphorylation Lip to MEK Specificity. *J. Biol. Chem.*, in press 1996.
95. Jeffrey A. Frost, Helge Steen, Peter Shaw, and Melanie H. Cobb. Cooperation of Raf and Rac in Activation of MAP Kinase and Cell Transformation. Submitted, 1996.
96. Mary Gilbreth, Peirong Yang, Dan Wang, Jeff Frost, Anthony Polverino, Melanie H. Cobb, and Stevan Marcus. The Highly Conserved *skb1* Gene Encodes a Protein That Interacts With Shk1, a Fission Yeast Ste20/PAK Homolog. In press, 1996.
97. Jennifer L. Swantek, Melanie H. Cobb, and Thomas D. Geppert. Translational Regulation of TNF Biosynthesis is Mediated by JNK/SAPK. Submitted, 1996.
98. Shih Khoo and Melanie H. Cobb. Activation of MAP Kinase by Glucose Is Not Required for Insulin Secretion. Submitted, 1996.

99. Andrei Khokhlatchev, Shuichan Xu, Jessie English, Eric Schaefer, and Melanie H. Cobb. Expression of MAP Kinase Cascade Components in Bacteria and Characterization of Active Components. In preparation, 1996.

**PERSONEL PAID FROM THIS GRANT:**

Derk Binns  
Shelia Coleman  
Vuong Do  
Jessie English (Hepler)  
Amanda Weitz  
Sarah Witt